PF-08046031

N/A

Report date: 2026/03/19 20:00:18

First In Class

Base Information

Drug NamePF-08046031

Drug Alias NamePF-08046031

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload

Mechanisms of ActionAnti-MelanotransferrinTubulin inhibitors

TargetsMelanotransferrinTubulin

Therapy Area/IndicationsSolid tumoursMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSwedenUnited Kingdom +[5]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursMelanoma

Other Information

ATC CodeN/A